MedTrace Logo

Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

NCT02132234 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2014-05-07

No results posted yet for this study

Summary

The aim of this study is to evaluate the influence of anti tumor necrosis factor-alpha (TNF-α) treatment on blood pressure, endothelial function and immune cell phenotype in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

Conditions

Interventions

DRUG

Etanercept

biological treatment according to rheumatologic indication

DRUG

Adalimumab

biological treatment according to rheumatologic indication

DRUG

Certolizumab

biological treatment according to rheumatologic indication

DRUG

Infliximab

biological treatment according to rheumatologic indication

Sponsors & Collaborators

  • Departmet of Rheumatology, J Dietl Hospital, Krakow, Poland

    collaborator UNKNOWN

  • Jagiellonian University

    lead OTHER

Principal Investigators

  • Tomasz Guzik, MD, PhD · Jagiellonian University

  • Bogdan Batko, MD, PhD · Department of Rheumatology, J. Dietl Hospital, Krakow, Poland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-07-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02132234 on ClinicalTrials.gov